ライフサイエンスコーパス: rosiglitazone

1 % of the activation of the positive control (rosiglitazone).

2 played iWAT browning, even in the absence of rosiglitazone.

3 tures were treated with the PPARgamma ligand rosiglitazone.

4 sly reported amorfrutins, similar to that of rosiglitazone.

5 e loss side effect of the PPAR-gamma agonist rosiglitazone.

6 types may be different for pioglitazone and rosiglitazone.

7 ytes was increased by the anti-diabetic drug rosiglitazone.

8 edema side effects of the PPARgamma agonist rosiglitazone.

9 erent from metformin alone or metformin plus rosiglitazone.

10 ly, down-regulated by the anti-diabetic drug rosiglitazone.

11 sis by AFC was also attenuated compared with rosiglitazone.

12 e-proliferator-activated receptor-gamma with rosiglitazone.

13 roliferator-activated receptor-gamma agonist Rosiglitazone.

14 activated receptor-gamma (PPARgamma) ligand, rosiglitazone.

15 different from responses induced by the TZD rosiglitazone.

16 c acid (13-HODE) and thiazolidinedione (TZD)-rosiglitazone.

17 creased mainly in women randomly assigned to rosiglitazone.

18 ta was also up-regulated by pioglitazone and rosiglitazone.

19 effect profile compared to the full agonist rosiglitazone.

20 d) in the presence of the PPARgamma agonist, rosiglitazone.

21 an the median expected percentage prescribed rosiglitazone.

22 ical response to antidiabetic treatment with rosiglitazone.

23 gonists such as TZD diabetes drugs including rosiglitazone.

24 t but also impairs the anti-tumor effects of rosiglitazone.

25 ates the anti-tumor effects of PPARgamma and rosiglitazone.

26 ) or without (n = 8) the anti-diabetes drug, rosiglitazone.

27 weight and with effectiveness comparable to rosiglitazone.

28 , is reversed by the upregulation of NRF2 by rosiglitazone.

29 alter the activity of the anti-diabetic drug rosiglitazone.

30 reatment of mice with the insulin sensitizer rosiglitazone.

31 ator-activated receptor gamma sensitivity to rosiglitazone.

32 Supplementing the diet with rosiglitazone (1.5 mg/g body weight) for an additional 4

33 ted for 7 days with metformin (10 mM) and/or rosiglitazone (10 muM).

34 endently up-regulated IGF-1R protein levels (rosiglitazone, 10 mumol/liter, 67% increase, n = 4, p <

35 ollows: 1) metformin (100 mg/kg per day), 2) rosiglitazone (2 mg/kg per day), and 3) no drug.

36 sistance were randomized to rhGH 3 mg daily, rosiglitazone 4 mg twice daily, combination rhGH + rosig

37 etformin alone or to metformin combined with rosiglitazone (4 mg twice a day) or a lifestyle-interven

38 signed to receive either 4 mg twice-daily of rosiglitazone, 4 mg of rosiglitazone and 500 mg of metfo

39 to the known insulin-sensitizing effects of rosiglitazone (6 mg kg(-1) day(-1) ).

40 ently evaluated the therapeutic potential of rosiglitazone (6 mg/kg at 5 min, 6 h and 24 h; i.p.) fol

41 7 days with metformin (250 mg/kg/day) and/or rosiglitazone (8 mg/kg/day).

42 and anemia characteristics of treatment with rosiglitazone (a TZD).

43 Rosiglitazone, a blood-brain barrier-impermeant PPARgamm

44 In our type 2 diabetes/obesity model, rosiglitazone, a peroxisome proliferator-activated recep

45 tment of selenium-deficient macrophages with rosiglitazone, a peroxisome proliferator-activated recep

46 Rosiglitazone, a peroxisome proliferator-activated recep

47 Here we show that rosiglitazone, a PPAR-gamma agonist, rescued the dendrit

48 egulation by TNFalpha, which was reversed by rosiglitazone, a result consistent with altered high man

49 tion or when mice were treated for 1 wk with rosiglitazone, a specific agonist of peroxisome prolifer

50 Rosiglitazone, a specific peroxisome proliferator-activa

51 Recent studies have associated rosiglitazone, a thiazolidinedione drug, with adverse ca

52 Rosiglitazone, a well known insulin sensitizer, stimulat

53 roliferator-activated receptor-gamma agonist rosiglitazone abrogated diet-induced mammary growth.

54 The addition of rosiglitazone abrogated the adverse effects of rhGH on i

55 that ped/pea-15 repression may contribute to rosiglitazone action on glucose disposal.

56 down-regulation, whereas metformin reversed rosiglitazone activity at the translational level.

57 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activators.

58 glitazone and -22.7% in rhGH) but not in the rosiglitazone alone (-2.5%) or control arms (-1.9%).

59 and losartan confers no greater benefit than rosiglitazone alone with respect to histopathology.

60 rsus rosiglitazone and losartan, compared to rosiglitazone alone, after 48 weeks of therapy.

61 The insulin-sensitizing drug rosiglitazone also increases the expression of CTRP13 in

62 adverse effect, and long-term treatment with rosiglitazone altered liver enzymes and caused hepatic f

63 5 expression and caused nonresponsiveness to rosiglitazone, although c-jun overexpression enhanced th

64 insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat

65 gnificantly in the rhGH arms (-17.5% in rhGH/rosiglitazone and -22.7% in rhGH) but not in the rosigli

66 r 4 mg twice-daily of rosiglitazone, 4 mg of rosiglitazone and 500 mg of metformin twice-daily, or 4

67 Supplementing with PPARgamma agonists rosiglitazone and GW1929 was sufficient to restore M2 di

68 dipose tissue remodeling similar to those of rosiglitazone and had enhanced antiinflammatory effects.

69 following exposure to the anti-diabetic drug rosiglitazone and increased circulating levels in adipon

70 therapy with rosiglitazone and metformin or rosiglitazone and losartan confers no greater benefit th

71 litazone and metformin in combination versus rosiglitazone and losartan, compared to rosiglitazone al

72 en-label trial was to assess the efficacy of rosiglitazone and metformin in combination versus rosigl

73 orty-eight weeks of combination therapy with rosiglitazone and metformin or rosiglitazone and losarta

74 igate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT1 activity/expressio

75 by anti-diabetic PPARgamma ligands, such as rosiglitazone and MRL24.

76 PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use for t

77 Microarray analysis revealed that while rosiglitazone and pioglitazone had little effect on gene

78 Compound 6 exhibited comparable efficacy to rosiglitazone and pioglitazone in vivo.

79 some proliferator-activated receptor ligands rosiglitazone and pioglitazone inhibited CYP26A1 with IC

80 Whereas rosiglitazone and pioglitazone potentiated cell death, t

81 Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are peroxisome prolifera

82 ects of thiazolidinediones (TZDs), including rosiglitazone and pioglitazone, on cardiac tissue.

83 We tested the effect of two TZD class drugs, rosiglitazone and pioglitazone, on human aortic smooth m

84 (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone.

85 ceptor phosphorylation, and this response to rosiglitazone and possibly to pioglitazone was PPARgamma

86 We used rosiglitazone and primary adipocytes to stringently eval

87 These compounds were far better than rosiglitazone and the other isolated compounds in enhanc

88 ompared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists.

89 termine, L-phenylepherine, proglitazone, and rosiglitazone) and seven interferences chosen from off-t

90 duced CH, mice were fed a high-fat diet with rosiglitazone, and cardiac and metabolic consequences we

91 of 234) for metformin alone, metformin plus rosiglitazone, and metformin plus lifestyle intervention

92 ction and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior

93 in resistance, and PPARgamma ligands such as rosiglitazone are insulin sensitizing, yet the mechanism

94 e thiazolidinediones (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPARgamma agonists

95 lts suggest that the behavioral responses to rosiglitazone are mediated through PPARgamma-dependent i

96 approved thiazolidinediones pioglitazone and rosiglitazone are peroxisome proliferator-activated rece

97 for human psoriasis, that is, Etanercept and Rosiglitazone, are effective in alleviating the symptoms

98 Using rosiglitazone as a model PPARgamma agonist, which decrea

99 used the facility proportion of patients on rosiglitazone as the predictor (instrumental variable ap

100 In this study, we show that, in L6 cells, rosiglitazone- as well as pioglitazone-dependent activat

101 Rosiglitazone attenuated bleomycin-induced skin inflamma

102 hereas treatment with the insulin sensitizer rosiglitazone attenuated both metabolic syndrome and ath

103 lled clinical trial compared the efficacy of rosiglitazone (Avandia; GlaxoSmithKline, Philadelphia, P

104 the adiponectin production was prevented by rosiglitazone but not by antioxidants.

105 th AFC improved glucose tolerance similar to rosiglitazone, but AFC did not promote weight gain to th

106 The addition of rosiglitazone, but not an intensive lifestyle interventi

107 Treatment by the PPARgamma ligand rosiglitazone, but not PI3K modulators, rescued colorect

108 For colorectal cancer, rosiglitazone, but not pioglitazone, was associated with

109 ype mice with LPS and the PPARgamma agonist, rosiglitazone, but not the PPARalpha agonist (WY-14643),

110 metabolism genes in the heart was altered by rosiglitazone, but these changes were not attenuated by

111 treatment of mice with the PPARgamma agonist rosiglitazone caused a greater improvement in in vivo in

112 The adjusted hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% c

113 vents per 100 person-years of treatment with rosiglitazone compared with pioglitazone.

114 nd mortality associated with prescription of rosiglitazone, compared with other oral hypoglycemic age

115 Rosiglitazone deactivated the mitogen-activated protein

116 roliferator-activated receptor gamma agonist rosiglitazone decreased activator protein 1 promoter act

117 MC neurons induced by the PPAR-gamma agonist rosiglitazone decreased ROS levels and increased food in

118 Rosiglitazone did not affect LV remodeling, increased pe

119 In control mice, rosiglitazone did not alter plasma aldosterone levels or

120 ny possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall card

121 Rosiglitazone-driven adipogenic differentiation of both

122 nal assays in hiPSC-CMs using tacrolimus and rosiglitazone, drugs targeting pathways predicted to pro

123 an EC(50) of 0.045 microM (compare with the rosiglitazone EC(50) of 0.067 microM), while the 13-NO(2

124 g to the ped/pea-15 promoter and blocked the rosiglitazone effect.

125 Rosiglitazone effects on cdc42 activation and Caco-2 ShP

126 lormethiazide, but not amiloride, attenuated rosiglitazone effects on volume expansion and CH.

127 Rosiglitazone enhanced insulin-induced glucose uptake in

128 The cardiovascular effects of rosiglitazone for patients with coronary artery disease

129 tive pathway and the increased inhibition by rosiglitazone G confirmed the sensitivity of the bacteri

130 vity of AasC was sensitive to triacsin C and rosiglitazone G.

131 spital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (

132 321 people in the rosiglitazone group and 323 in the active control group

133 Mean HbA(1c) was lower in the rosiglitazone group than in the control group at 5 years

134 ral hypoglycemic agents, patients prescribed rosiglitazone had significantly higher all-cause (hazard

135 atients who had diabetes and were prescribed rosiglitazone had significantly higher all-cause mortali

136 Rosiglitazone has no effect on chloride secretion in the

137 In contrast, rosiglitazone has no effect on ENaC activity.

138 ed PPARgamma full agonists, pioglitazone and rosiglitazone, have been reported to produce serious adv

139 , but activates GLUT4 to a similar degree as rosiglitazone, implying gene-specific partial agonism.

140 Rosiglitazone improves glycemic control for patients wit

141 activated receptor-gamma (PPARgamma) agonist rosiglitazone improves hippocampus-dependent cognitive d

142 at retains similar anti-diabetic efficacy as rosiglitazone in mice yet does not elicit weight gain or

143 ells induced by a specific PPARgamma agonist rosiglitazone in mice.

144 king pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of

145 Administration of rosiglitazone in T1DM-2W mice up-regulated the expressio

146 two insulin-sensitizing drugs (metformin and rosiglitazone) in a genetic model of spontaneously hyper

147 lta12,14-prostaglandin J2, troglitazone, and rosiglitazone) in cat corneal fibroblasts.

148 of the glitazone scaffold, pioglitazone and rosiglitazone, in an effort to identify off-target bindi

149 The PPARgamma agonist rosiglitazone increases insulin sensitivity and is effec

150 These results suggest that rosiglitazone increases PHD expression in a PPARgamma-de

151 reviously, we reported that pioglitazone and rosiglitazone induce osteocyte apoptosis and sclerostin

152 phosphorylated at serine 112 but had reduced rosiglitazone-induced activity at lipogenic genes.

153 (PHD) levels significantly increased during rosiglitazone-induced adipocyte differentiation (RIAD).

154 PARgamma-selective antagonist GW9662 blocked rosiglitazone-induced adiponectin expression and antidep

155 Here we show that rosiglitazone-induced browning of human adipocytes activ

156 tor in human adipocytes that is required for rosiglitazone-induced browning, including the increase i

157 etic furosemide in wild-type mice attenuated rosiglitazone-induced CH, hypertrophic gene reprogrammin

158 esis that volume expansion directly mediates rosiglitazone-induced CH, mice were fed a high-fat diet

159 in the collecting duct, but still exhibited rosiglitazone-induced fluid retention.

160 iglitazone, Pparg-BKO mice were resistant to rosiglitazone-induced hyperphagia and weight gain and, r

161 al triglyceride accumulation relative to the rosiglitazone-induced maximum.

162 d not modify PepT1 activity but counteracted rosiglitazone-induced PepT1-mediated transport.

163 suppressed PPARgamma expression and blocked rosiglitazone-induced pre-adipocyte differentiation towa

164 2 demonstrated this residue as essential for rosiglitazone-induced receptor activation, but nonessent

165 owed loss of PPARgamma and were resistant to rosiglitazone-induced WAT differentiation.

166 receptor gamma (PPARgamma) agonists such as rosiglitazone induces browning of rodent and human adipo

167 Pretreatment with rosiglitazone inhibited the Ang II-induced expression of

168 Both pretreatment and posttreatment with rosiglitazone inhibited the occurrence of fatal rupture

169 Ten-day rosiglitazone injection not only improved the response t

170 There was no significant rhGH x rosiglitazone interaction for any body composition param

171 Rosiglitazone is an insulin sensitiser used in combinati

172 The use of pioglitazone and rosiglitazone is associated with a decreased liver cance

173 As rosiglitazone is clinically used to treat diabetes, our

174 uction of lesions in animals pretreated with rosiglitazone is concomitant with decreased expression o

175 ARgamma phosphorylation in obese patients by rosiglitazone is very tightly associated with the anti-d

176 e activity could be enhanced by lanthanum or rosiglitazone, known stimulators of TRPC5 and TRPC5-cont

177 owever, in subcutaneous inguinal fat (iWAT), rosiglitazone markedly induced molecular signatures of b

178 Studies have suggested that the use of rosiglitazone may be associated with an increased risk o

179 er region of PHDs by ChIP-PCR, implying that rosiglitazone may induce PHD up-regulation directly by P

180 Importantly, rosiglitazone-mediated whole-body metabolic improvements

181 were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined

182 able adjustment, among patients treated with rosiglitazone, mortality was similar (hazard ratio [HR],

183 spanic black participants and metformin plus rosiglitazone most effective in girls.

184 f 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin

185 oliferator-activated receptor-gamma) agonist rosiglitazone, Noc expression was enhanced 30-fold.

186 PP5 are resistant to the negative effects of rosiglitazone on bone, which in wild type animals causes

187 ation of IGF-1R, we determined the effect of rosiglitazone on oxidized LDL (oxLDL)-induced apoptosis.

188 idyl ether or GW9662) blunted the effects of rosiglitazone on PHD regulation.

189 el, separate treatment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially

190 oglitazone use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidi

191 Moreover, treatment with rosiglitazone or pioglitazone did not significantly alte

192 ge, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D

193 er cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitaz

194 Treating epithelial cells with synthetic (rosiglitazone) or endogenous (10-nitro-oleic acid) PPARg

195 However, when Ucp1 was activated by rosiglitazone, or by iWAT browning in cold-exposed or yo

196 Treatment with pioglitazone, rosiglitazone, or dexamethasone significantly protected

197 itazone 4 mg twice daily, combination rhGH + rosiglitazone, or double placebo (control) for 12 weeks.

198 inhibitor phloridzin, the insulin-sensitizer rosiglitazone, or insulin.

199 ds repress Retn transcription in adipocytes, rosiglitazone paradoxically stimulates the enhancer acti

200 nt mice with the synthetic PPAR-gamma ligand rosiglitazone partially normalizes the altered gene expr

201 All three PPARgamma ligands (rosiglitazone, pioglitazone, and 15-deoxy-Delta(12,14)-p

202 Pioglitazone and rosiglitazone possess a common functional core, glitazon

203 In the presence of rosiglitazone, PP5 translocates to the nucleus, binds to

204 When treated with the TZD rosiglitazone, Pparg-BKO mice were resistant to rosiglit

205 lta(12,14)-prostaglandin J(2)) or synthetic (rosiglitazone) PPARgamma ligands enhanced B cell prolife

206 PPARgamma activation by rosiglitazone prevented the mitochondrial dysfunction an

207 planted fibroblasts and skin organ cultures, rosiglitazone prevented the stimulation of collagen gene

208 -term treatment with metformin, but not with rosiglitazone, prevents the development of severe CHF in

209 Both nitrite and rosiglitazone produced improvements, relative to saline,

210 ) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic c

211 ses of bexarotene with the PPARgamma agonist rosiglitazone provides effective growth suppression of m

212 lls, we show that activation of PPARgamma by rosiglitazone reduced follistatin mRNA levels in a dose-

213 20 mumol/liter of rosiglitazone reduced oxidized LDL-induced apoptosis by

214 erentiation induced by the PPARgamma agonist rosiglitazone, reduced obesity development and ameliorat

215 s report, we show that the PPARgamma agonist rosiglitazone reduces autoantibody production, renal dis

216 Remarkably, rosiglitazone restored insulin secretion in response to

217 e, PPARgamma activation (i.e. treatment with rosiglitazone) restored euglycemia and reversed high fat

218 ation of human aortic endothelial cells with rosiglitazone resulted in the time- and dose-dependent s

219 Treatment with the PPAR-gamma agonist rosiglitazone reversed the phenotype.

220 Here, rosiglitazone (RGZ) activation of GPR40 and p38 MAPK was

221 The insulin sensitizing glitazone drugs, rosiglitazone (ROS) and pioglitazone (PGZ) both have ant

222 tivated Receptor gamma (PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-d

223 We found that rosiglitazone (Rosi) significantly improved insulin sens

224 or (PPARgamma) ligands pioglitazone (Pio) or rosiglitazone (Rosi) to TGF-beta-treated orbital fibrobl

225 liferation-activated receptor-gamma agonist, rosiglitazone (Rosi), a medication recently reintroduced

226 ted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases foo

227 utic potential of this pathway, we examined, rosiglitazone (Rosi), a PPARgamma agonist, which has bee

228 to DMSO vehicle, the pharmaceutical obesogen rosiglitazone (ROSI), or TBT (5.42, 54.2, or 542 nM) thr

229 ompared to the multi-billion dollar TZD drug rosiglitazone (Rosi).

230 stimulating cells with the PPARgamma agonist rosiglitazone (Rosi).

231 rator-activated receptor (PPAR)gamma agonist rosiglitazone (RSG) but the consequence of this interact

232 activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cogni

233 The PPARgamma agonist rosiglitazone (RSG) promoted quiescence in the activated

234 term labor and that PPARgamma activation via rosiglitazone (RSG) would attenuate the macrophage-media

235 gonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe si

236 Here we show that rosiglitazone significantly increased dendritic spine de

237 conclude that mesalamine, sulfasalazine, and rosiglitazone significantly reduced the cellular express

238 Stimulation of PPAR-gamma in vivo (rosiglitazone) significantly attenuates biliary damage a

239 Rosiglitazone stimulated an increase in the ADP/ATP rati

240 ndothelial cells, and LKB1 was essential for rosiglitazone-stimulated AMPK activity in HeLa cells.

241 the role of AMP-activated protein kinase in rosiglitazone-stimulated NO synthesis.

242 MP-activated protein kinase mutant abrogated rosiglitazone-stimulated Ser-1177 phosphorylation and NO

243 ive capacity are maintained independently of rosiglitazone, suggesting that additional browning facto

244 f this NOC-peptide was partially reversed by rosiglitazone, suggesting that effect of NOC on PPAR-gam

245 accumulation compared with that triggered by rosiglitazone, suggesting that LT175 may have a lower ad

246 R3) counteracted this rescue, suggesting the rosiglitazone survival effect was, at least in part, med

247 Moreover, upon coadministration with rosiglitazone, T2384 was able to antagonize the side eff

248 prevented by suramin, a PTP1B inhibitor, or rosiglitazone that decreased PTP1B levels.

249 ed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compar

250 y-resistant and -sensitive mice treated with rosiglitazone to generate candidate brite biomarkers fro

251 Addition of rosiglitazone to glucose-lowering therapy in people with

252 ce, an effect associated with the failure of rosiglitazone to improve liver insulin receptor signal t

253 FP407 was required for the PPARgamma agonist rosiglitazone to increase Glut4 expression, but was not

254 ith in vitro results, oral administration of rosiglitazone to ob/ob mice for 2 weeks increased adipos

255 We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects

256 hyperphagia and weight gain and, relative to rosiglitazone-treated Pparg(f/f) mice, experienced only

257 le to antagonize the side effects induced by rosiglitazone treatment alone while retaining robust eff

258 Collectively, these results indicate that rosiglitazone treatment attenuates inflammation, dermal

259 se in hepatic insulin sensitivity induced by rosiglitazone treatment during HFD feeding was completel

260 duced insulin-resistant mice and improved by rosiglitazone treatment in the latter.

261 A 7-day rosiglitazone treatment increased PepT1 activity and pre

262 Rosiglitazone treatment induced volume expansion and CH

263 ternal-fetal interface and systemically, and rosiglitazone treatment partially attenuated these respo

264 In these experiments, rosiglitazone treatment reduced c-JUN presence at the PE

265 Rosiglitazone treatment reduced the induction of the ear

266 Rosiglitazone treatment restored insulin sensitivity in

267 In addition, rosiglitazone treatment significantly decreased the cort

268 logical concentrations of Adn resulting from rosiglitazone treatment suppressed regeneration by reduc

269 logical concentrations of Adn resulting from rosiglitazone treatment suppressed regeneration by reduc

270 As with the in vivo studies, rosiglitazone treatment up-regulated PepT1 transport act

271 matched analysis supported an association of rosiglitazone treatment with an increase in major ischem

272 ted receptor (PPAR)gamma activation, through rosiglitazone treatment, reduced the rate of alpha-GalCe

273 Furthermore, rosiglitazone treatment, which promotes redistribution o

274 vels, although these effects were reduced by rosiglitazone treatment.

275 ckdown of PP5 results in cells refractory to rosiglitazone treatment.

276 espectively; this suppression was rescued by rosiglitazone treatment.

277 All of these effects were blunted after rosiglitazone treatment.

278 y distinct PPARgamma agonists [pioglitazone, rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-pro

279 Herein, we show that PPARgamma ligands (rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-pro

280 500 mg of metformin twice-daily, or 4 mg of rosiglitazone twice-daily and 50 mg of losartan once-dai

281 eptor (PPAR) gamma agonists pioglitazone and rosiglitazone up-regulated CYP26B1 transcription by as m

282 tic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates PPAR-gamma-dependent genes,

283 To examine any association between rosiglitazone use and cardiovascular events among patien

284 findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cau

285 showed more favorable changes over time with rosiglitazone versus metformin or glyburide.

286 ars of follow-up among patients treated with rosiglitazone versus patients not receiving a thiazolidi

287 rescription of pioglitazone, prescription of rosiglitazone was associated with an increased risk of s

288 ve to saline and rosiglitazone, whereas only rosiglitazone was effective at reducing hepatic glucose

289 Rosiglitazone was given 1 week before infusion and 1 wee

290 Inhibition of follistatin expression by rosiglitazone was not associated with decreased follista

291 Metformin plus rosiglitazone was superior to metformin alone (P=0.006);

292 A novel effect of rosiglitazone was to increase expression of Nrf2 (nuclea

293 Rosiglitazone was used as a positive control.

294 rotic process in vivo, the synthetic agonist rosiglitazone was used in a mouse model of scleroderma.

295 These effects of rosiglitazone were absent in mice lacking adiponectin bu

296 lthough the maximal efficacies of INT131 and rosiglitazone were similar with respect to improvements

297 owered blood pressure relative to saline and rosiglitazone, whereas only rosiglitazone was effective

298 re, the combination of the PPARgamma agonist rosiglitazone with bexarotene synergistically suppressed

299 AFC activated PPARgamma as effectively as rosiglitazone with regard to Adrp, Angptl4, and AdipoQ,

300 The hypothesis that rosiglitazone would reduce aneurysm expansion or rupture